Cargando…
COT-17 EFFECT OF BEVACIZUMAB AGAINST CYSTIC COMPONENT OF PRIMARY/METASTATIC BRAIN TUMORS
BACKGROUND: Bevacizumab (BEV) improves the symptom via reducing the peritumoral edema and sometimes via reducing the size of brain tumor. However,the effect of BEV against cystic part of brain tumor has not been documented yet. In this report,we investigated the effect of BEV on cystic component of...
Autores principales: | Yamasaki, Fumiyuki, Takano, Motoki, Yonezawa, Ushio, Taguchi, Akira, Onishi, Shumpei, Kurisu, Kaoru, Sugiyama, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213219/ http://dx.doi.org/10.1093/noajnl/vdz039.197 |
Ejemplares similares
-
Effect of bevacizumab against cystic components of brain tumors
por: Yamasaki, Fumiyuki, et al.
Publicado: (2019) -
NI-17 T2-FLAIR MISMATCH SIGN IN DIFFUSE GLIOMA AND DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMOR
por: Onishi, Shumpei, et al.
Publicado: (2019) -
COT-04 Circulating biomarker for glioblastoma and primary central nervous system lymphoma -Next Generation Sequencing of small noncoding RNA-
por: Onishi, Shumpei, et al.
Publicado: (2020) -
COT-11 Relationship between preoperative liquid biopsy and prognosis of glioblastoma -Next Generation Sequencing of small noncoding RNA-
por: Onishi, Shumpei, et al.
Publicado: (2021) -
NI-11 Clinical significance of intracystic diffusion hyperintensity lesions remaining after treatment of intracranial germ cell tumor
por: Takano, Motoki, et al.
Publicado: (2020)